Litronesib (LY2523355) is a selective Eg5 inhibitor. Litronesib (25 nM) induces cancer cells to death during mitotic arrest, and this needs sustained activation of spindle-assembly checkpoint (SAC)[1].

Litronesib (LY2523355; 1.1, 3.3, 10, and 30 mg/kg, i.v.) displays antitumor activity in a dose-dependently. It also leads to a dramatic increase in cancer cells immuno-positive for histone H3 phosphorylation in Colo205 xenograft tumors[1].